Presence of antibody to bovine apoB-100 in patients receiving therapeutic cell populations cultured in FCS
| Infusion no. . | Time after infusion . | Presence of bovine* ApoB-100 antibody . |
|---|---|---|
| GT trial | ||
| Patient 1: 11 | 13 y | − |
| Patient 2: 12 | 13 y | ++ |
| BCV trial | ||
| Patient A | ||
| Preinfusion | NA | − |
| 4 | 4 wk | +++ |
| Patient B | ||
| Preinfusion | NA | SNA |
| 8 | 4 wk | ++++ |
| Patient C | ||
| Preinfusion | NA | SNA |
| 2 | 20 wk | +/− |
| Patient D | ||
| Preinfusion | NA | SNA |
| 8 | 4 wk | ++ |
| Patient E | ||
| Preinfusion | NA | − |
| 4 | 4 wk | + |
| 5 | 4 wk | ++ |
| Patient F | ||
| Preinfusion | NA | SNA |
| 2 | 2 wk | − |
| Patient G | ||
| Preinfusion | NA | SNA |
| 2 | 3 wk | + |
| Infusion no. . | Time after infusion . | Presence of bovine* ApoB-100 antibody . |
|---|---|---|
| GT trial | ||
| Patient 1: 11 | 13 y | − |
| Patient 2: 12 | 13 y | ++ |
| BCV trial | ||
| Patient A | ||
| Preinfusion | NA | − |
| 4 | 4 wk | +++ |
| Patient B | ||
| Preinfusion | NA | SNA |
| 8 | 4 wk | ++++ |
| Patient C | ||
| Preinfusion | NA | SNA |
| 2 | 20 wk | +/− |
| Patient D | ||
| Preinfusion | NA | SNA |
| 8 | 4 wk | ++ |
| Patient E | ||
| Preinfusion | NA | − |
| 4 | 4 wk | + |
| 5 | 4 wk | ++ |
| Patient F | ||
| Preinfusion | NA | SNA |
| 2 | 2 wk | − |
| Patient G | ||
| Preinfusion | NA | SNA |
| 2 | 3 wk | + |
The FCS lysate was immunoprecipitated with 10 μL of each serum and the precipitants analyzed by SDS-PAGE.
GT trial indicates gene therapy trial for adenosine deaminase (ADA) deficiency; BCV trial, breast cancer vaccine trial; NA, not applicable; SNA, sample not available.
Reference band intensity: — indicates ≤ 0%; +/−, 0%-20%; +, 20%-60%; ++, 60%-100%; +++, 100%-140%; ++++, >140%.